Skip to main content

Table 1 Baseline characteristics

From: Relationship between treatment delay and final infarct size in STEMI patients treated with abciximab and primary PCI

  FMC to patent artery < 90 min (N = 48) FMC to patent artery ≥ 90 min (N = 41) Pvalue
Age, years (SD) 61.8 (9.7) 62.9 (9.8) 0.62
Women 5 (10.4) 9 (22.0) 0.14
Risk factors    
   Diabetes Mellitus 4 (8.3) 1 (2.4) 0.37
   Hypertension 12 (25.0) 13 (31.7) 0.48
   Current smoker 21 (43.8) 18 (43.9) 0.99
   Hyperlipidemia 1 (2.1) 3 (7.3) 0.33
Previous Revascularization 0 (0) 0 (0)  
Creatinine clearance ml/min (SD) 81 (23.1) 74 (18.6) 0.60
Clinical presentation    
   Systolic blood pressure, mmHg (SD) 145 (29.6) 136 (26.4) 0.12
   Heart rate, beats/min (SD) 70 (14) 66 (14) 0.18
   Presentation off hours 27 (56.3) 32 (78.0) 0.03
   Admission with ambulance 44 (91.7) 34 (82.9) 0.21
   Pretreatment with abciximab 37 (77.1) 33 (80.5) 0.70
Time delays, median, minutes (IQR)    
   Symptom to FMC 91 (51-191) 90 (28-229) 0.43
   FMC to angiography 66 (58-79) 93 (85-116) 0.0005
   FMC to patent artery 78 (68-83) 107 (100-131) 0.0005
   FMC to balloon 84 (76-100) 111 (104-140) 0.0005
   Symptom to abciximab 150 (80-195) 160 (78-285) 0.48
   Abciximab to PCI 53 (33-68) 63 (43-78) 0.13
  1. Data are presented as counts (percentage) if not otherwise indicated. SD Standard Deviation. IQR Interquartile range. FMC, First Medical Contact. Creatinine clearance calculated Cockroft Gault formula ((140 - Age) * (Wt in kg) * (0.85 if female)/(72 * cr) (Plasma Creatinine * 0.8136)). PCI Percutaneous coronary intervention